(Sharecast News) - Pfizer posted better-than-expected fourth-quarter results on Tuesday, helped by steady demand for established medicines that offset a sharp slide in Covid-related sales, but the drugmaker's reaffirmed 2026 outlook remained below some Wall Street forecasts, weighing on the shares in early trading.
Chairman and chief executive officer Albert Bourla...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE